SparingVision Raises €44.5 Million
About SPVN06
SPVN06 is a breakthrough treatment for retinitis pigmentosa, an orphan inherited retinal disease which leads to blindness and affects nearly two million people worldwide.
We are a biotechnology company focused on the discovery and development of genomic medicines for the treatment of blinding inherited retinal diseases.
Bringing innovative treatments to physicians and patients to address serious ocular disorders.
SPVN06 is a breakthrough treatment for retinitis pigmentosa, an orphan inherited retinal disease which leads to blindness and affects nearly two million people worldwide.
Our lead product, SPVN06 is a breakthrough therapy for retinitis pigmentosa (RP), an orphan inherited retinal disease which leads to blindness and affects nearly two million individuals worldwide....
MUTATIONS IN MORE THAN 70 GENES ARE KNOWN TO CAUSE RP
PEOPLE AFFECTED BY RP IN THE WORLD
PEOPLE AFFECTED BY RP IN FRANCE
Presentation of our company
Download pdf